Dual Kidney Transplantation: A Review of Past and Prospect for Future

Table 2

Recipient characteristics DKT versus SKT.

Author	Journal/year/number of recipient	DKT					SKT
		Age	Immunosuppression	Weight	BMI	Comorbid	Age (years)	Weight	BMI	Comorbid
Remuzzi et al. [16]	Journal of American Society of Nephrology/1999/24 DKT	59.4 ± 9.9	Prednisolone, Cyclosporine & mycophenolate mofetil. No comment on induction	71.4 ± 19.1	25.3 ± 5.4	HTN 77.3%; DM 4.4%	50.2 ± 12.1	73.1 ± 16.2	25.3 ± 4.7	HTN 71.7%; DM 6.4%
Lu et al. [20]	Archives of Surgery/1999/50 DKT	57 ± 11	Cyclosporine, steroids & MMF or AZA. Induction with OKT3 or IL-2 inhibitor	—	—	—	50 ± 12	—	—	—
Snanoudj et al. [24]	American Journal of Transplantation/2009/81 DKT	69.4 ± 3.0	Received IL-2 receptor antagonist or ATG. Cyclosporine or tacrolimus, prednisolone and MMF were used after induction	68.4 ± 14.1	24.3 ± 4.1	DM 18.5%; ischemic cardiopathy 18.2%	59.9 ± 6.3	72.8 ± 17.0	25.1 ± 4.7	DM 18.6%; Ischemic Cardiopathy 12.9%
Ekser et al. [19]	American Journal of Transplantation/2010/100 DKT	61.7 ± 5.6	Induction therapy consisted of antithymocyte globulin (ATG) or Basiliximab. Maintenance immunosuppressive sirolimus or everolimus either without a calcineurin inhibitor (CNI) or with a reduced CNI	—	25.5 ± 3.5		57.7 ± 8.6	—	24.5 ± 3.4	—
Klair et al. [28]	American Journal of Transplantation/2013/1308 DKT		No comment on immunosuppressive medications used	—	25.1	DM 37.5%; HTN 25.6%	49.6  ±  14.8	—	29.6	DM 28.4%; HTN 34.9%
Bunnapradist et al. [31]	Journal of American Society of Nephrology/403 DKT	55.1 ± 11.5	No comment on immunosuppressive medications used	77.1 ± 17.1	—	—	48.1 ± 13.7	77.4 ± 19.2	—	—

. HTN (hypertension), DM (diabetes mellitus), PRA (panel reactive antibody), HLA MM (human leukocyte antigen mismatches), M (male), F(female), MMF (mycophenolate mofetil), AZA(azathioprine), IL-2 (interleukin-2), ATG (antithymocyte globulin), and OKT3 (muromonab-CD3).